Compare MCHX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHX | ASRT |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 76.0M |
| IPO Year | 2003 | 2004 |
| Metric | MCHX | ASRT |
|---|---|---|
| Price | $1.36 | $13.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 10.6K | ★ 42.2K |
| Earning Date | 03-25-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $90,291,000.00 | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.70 | $16.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.26 | $0.51 |
| 52 Week High | $2.30 | $13.90 |
| Indicator | MCHX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 66.87 |
| Support Level | $1.35 | $0.69 |
| Resistance Level | $1.76 | N/A |
| Average True Range (ATR) | 0.06 | 0.65 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 0.00 | 78.95 |
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.